Cystic Fibrosis News Today Weekly Digest

Cystic Fibrosis Weekly Update Contents: The 4 Deaths that Mold Me Two Phase 3 Trials of Vertex’s Triple Combination Therapy with VX-659 Are Fully Enrolled The 4 Deaths that Mold Me Sep 11, 2018 09:00 am | Brad Dell Winter 2016-17: Sabrina Santos We called each other twins. Sabrina, like me, was a nerdy, faithful, coffee-loving journalist. She also had cystic fibrosis, Mycobacterium abscessus, deafness, and an urgent need for lung transplantation. Unlike me, she was fearless. Sabrina wielded titanic power. Her radiant eyes could shatter your world in the sweetest way, even over […] The post The 4 Deaths that Mold Me appeared first on Cystic Fibrosis News Today. Read More Two Phase 3 Trials of Vertex’s Triple Combination Therapy with VX-659 Are Fully Enrolled Sep 11, 2018 07:00 am | Vijaya Iyer Vertex Pharmaceuticals has completed enrollment for two phase 3 studies testing the triple combination therapy of its new CFTR corrector VX-659 together with tezacaftor (VX-661) and Kalydeco (ivacaftor) in patients with cystic fibrosis (CF). The studies focus on patients with two F508del mutations in the CFTR gene (the gene that is defective in CF), or one F508del mutation […] The post Two Phase 3 Trials of Vertex’s Triple Combination Therapy with VX-659 Are Fully Enrolled appeared first on Cystic Fibrosis News Today. Read More Recent News Grieving in an ‘Always Online’ World Vertex and Treating CF: 3 Disease-modifying Therapies Make Leap from Lab to Patients Reminders to Those Who Mourn Reimbursement Agreement Includes Orkambi in Public Health Plan for CF Patients in Australia Australian Museum Eureka Prize Given CF Research Team for Work on Bacteria’s Spread Among Patients